Lymphoma

A collection of features and news articles published in ASH Clinical News related to lymphoma.

FDA Approves Ibrutinib Combo for Waldenström Macroglobulinemia

The U.S. Food and Drug Administration (FDA) approved ibrutinib, in combination with rituximab, for the treatment of adult patients with Waldenström macroglobulinemia (WM). In...

Rituximab Plus Lenalidomide Noninferior to Chemotherapy in Treatment-Naïve Follicular Lymphoma

Treatment with the chemotherapy-free combination of rituximab and the immunomodulatory agent lenalidomide (R2) was noninferior to the combination of rituximab and chemotherapy (R-chemo) in...

Clinical Trials of Leukemia and Lymphoma Drug Placed on Hold

Pharmaceutical manufacturer Affimed has halted two trials of its CD19/CD3-targeting T-cell engager AFM11 following reports of three serious adverse events (AEs), including one patient...

FDA Panel Recommends Rituximab Biosimilar for Lymphoma

The U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) unanimously voted to recommend approval for CT-P10, a biosimilar of rituximab. The...

FDA Approves Duvelisib for Patients with CLL or SLL

The U.S. Food and Drug Administration has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia...

FDA Approves Mogamulizumab-kpkc for Two Types of Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome...

Can a Liquid Biopsy Predict Outcomes in DLBCL?

In a study of patients with diffuse large B-cell lymphoma (DLBCL), levels of pretreatment circulating tumor DNA (ctDNA) and molecular responses were independent predictors...

U.K. Says CAR-T Cell Therapy for Non-Hodgkin Lymphoma Is Too Expensive

The U.K.’s National Institute for Health and Care Excellence (NICE) has rejected the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel for use by...
WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...

Ibrutinib-Rituximab Combo Granted Priority Review

The FDA granted priority-review designation to the combination of ibrutinib and rituximab for the treatment of Waldenström macroglobulinemia (WM). The Bruton tyrosine kinase inhibitor...
Advertisement

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.